BioSpace News Archive

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Presentation Details: Date & Time: Tuesday, Septembe

VYNE Therapeutics Inc. completed its previously announced corporate name change from Menlo Therapeutics Inc. to VYNE Therapeutics Inc. and the change of its ticker symbol from “MNLO” to “VYNE”.

Empagliflozin also significantly reduced the relative risk of first and recurrent hospitalization for heart failure by 30 per cent and significantly slowed kidney function decline1

Agreement includes board position and exclusive negotiation period for further collaborative access to AuroLase® Therapy in other non-U.S. geographies.